Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Abstract

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Daniel E Furst, Michael H Schiff, Roy M Fleischmann, Vibeke Strand, Charles A Birbara, Daniele Compagnone, Steven A Fischkoff and Elliot K Chartash
The Journal of Rheumatology December 2003, 30 (12) 2563-2571;
Daniel E Furst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H Schiff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy M Fleischmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vibeke Strand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles A Birbara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniele Compagnone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A Fischkoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliot K Chartash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Article Information

vol. 30 no. 12 2563-2571
PubMed 
14719195

Published By 
The Journal of Rheumatology
Print ISSN 
0315-162X
Online ISSN 
1499-2752
History 
  • Published online December 1, 2003.


Author Information

  1. Daniel E Furst,
  2. Michael H Schiff,
  3. Roy M Fleischmann,
  4. Vibeke Strand,
  5. Charles A Birbara,
  6. Daniele Compagnone,
  7. Steven A Fischkoff, and
  8. Elliot K Chartash
  1. Division of Rheumatology, Department of Medicine, University of California-Los Angeles, 32-59 Rehabilitation Center, 1000 Veteran Avenue, Box 951670, Los Angeles, CA 90095-1670, USA. defurst@mednet.ucla.edu

Article usage

Article usage: January 2009 to November 2023

AbstractFullPdf
Jan 20093309
Feb 200954020
Mar 200956019
Apr 200964056
May 200952048
Jun 200945048
Jul 200947045
Aug 200962047
Sep 200956061
Oct 200982038
Nov 200957050
Dec 200947036
Jan 201053045
Feb 201068047
Mar 201096048
Apr 201088055
May 201059027
Jun 201051036
Jul 201043044
Aug 201063026
Sep 201047029
Oct 201047041
Nov 201052042
Dec 201042021
Jan 201164047
Feb 201156036
Mar 201174052
Apr 201145038
May 201138023
Jun 201156333
Jul 201156128
Aug 201150029
Sep 201161057
Oct 201150029
Nov 201143026
Dec 201159227
Jan 201259025
Feb 201275040
Mar 201291033
Apr 201275028
May 201271028
Jun 201246012
Jul 201241124
Aug 201249032
Sep 201246032
Oct 201263028
Nov 201280025
Dec 201238023
Jan 2013104019
Feb 201377124
Mar 2013108036
Apr 2013103039
May 201375028
Jun 201343027
Jul 201352032
Aug 201352025
Sep 201362021
Oct 201377021
Nov 201373019
Dec 201368010
Jan 201478023
Feb 201463028
Mar 201466133
Apr 201471018
May 201456015
Jun 201434023
Jul 201458019
Aug 201456021
Sep 201451020
Oct 201441116
Nov 201474025
Dec 201438014
Jan 201549027
Feb 201577024
Mar 2015129030
Apr 2015139014
May 201544011
Jun 201580021
Jul 201564016
Aug 2015125016
Sep 201543023
Oct 201557032
Nov 2015155020
Dec 2015120010
Jan 201650014
Feb 201666014
Mar 201661036
Apr 201661017
May 201662027
Jun 201630025
Jul 201638017
Aug 201649028
Sep 201656013
Oct 201652021
Nov 201663022
Dec 201654024
Jan 2017160025
Feb 2017255044
Mar 2017172056
Apr 2017144046
May 2017161039
Jun 2017111037
Jul 2017124039
Aug 201797025
Sep 2017156037
Oct 2017133030
Nov 2017147047
Dec 2017112033
Jan 2018135034
Feb 2018149014
Mar 2018230025
Apr 2018222025
May 2018128012
Jun 2018116011
Jul 2018136016
Aug 2018138010
Sep 201888014
Oct 201811209
Nov 2018141017
Dec 201813707
Jan 2019135014
Feb 201914808
Mar 2019262022
Apr 201918208
May 201996010
Jun 201999015
Jul 2019110017
Aug 20198204
Sep 2019138011
Oct 2019124012
Nov 2019137012
Dec 20198905
Jan 202050017
Feb 202063035
Mar 202082047
Apr 2020114065
May 202071042
Jun 202050032
Jul 202071029
Aug 202041026
Sep 202070018
Oct 202064026
Nov 202068042
Dec 202073028
Jan 202150040
Feb 202179029
Mar 2021103066
Apr 2021137060
May 202173031
Jun 202165029
Jul 20215304425
Aug 20211930145
Sep 202166026
Oct 202148026
Nov 202155030
Dec 202134019
Jan 202264062
Feb 202266026
Mar 202293058
Apr 202264036
May 202234031
Jun 202236013
Jul 202254040
Aug 202245037
Sep 202247020
Oct 202247041
Nov 202244036
Dec 202211010
Jan 2023162038
Feb 202357030
Mar 202389059
Apr 202348023
May 202381041
Jun 202341022
Jul 202345016
Aug 202328024
Sep 202341028
Oct 2023115022
Nov 2023104021

Statistics from Altmetric.com

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 30, Issue 12
1 Dec 2003
  • Table of Contents
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Daniel E Furst, Michael H Schiff, Roy M Fleischmann, Vibeke Strand, Charles A Birbara, Daniele Compagnone, Steven A Fischkoff, Elliot K Chartash
The Journal of Rheumatology Dec 2003, 30 (12) 2563-2571;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Daniel E Furst, Michael H Schiff, Roy M Fleischmann, Vibeke Strand, Charles A Birbara, Daniele Compagnone, Steven A Fischkoff, Elliot K Chartash
The Journal of Rheumatology Dec 2003, 30 (12) 2563-2571;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2023 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire